Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Trepel

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2008
Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in boneAkihiro Yano, Shinji Tsutsumi, Shiro Soga, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2012
Heat shock protein 90α (HSP90α), a substrate and chaperone of DNA-PK necessary for the apoptotic responseStéphanie Solier, Kurt W Kohn, Bradley Scroggins, et al.
Oncology Letters|December 2, 2015
Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case reportHelen Gharwan, Yusuke Tomita, Min-Jung Lee, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 22, 2006
Curcumin is an inhibitor of p300 histone acetylatransferaseMonica G Marcu, Yun-Jin Jung, Sunmin Lee, et al.
Cancer Research|November 25, 2003
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cellsWanping Xu, Xitong Yuan, Yun Jin Jung, et al.
Expert Review of Hematology|April 28, 2017
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injuryPedro Cabrales, Scott Caroen, Arnold Oronsky, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2003
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrugMartin J Edelman, Kenneth Bauer, Shyam Khanwani, et al.
Molecular Pharmacology|September 4, 2010
Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinomaHye-Sik Kong, Sunmin Lee, Kristin Beebe, et al.
Plos One|October 23, 2013
Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effectsDror Luger, Yu-An Yang, Asaf Raviv, et al.
Trends in Cancer|April 30, 2020
MGMT Status as a Clinical Biomarker in GlioblastomaMadison Butler, Lorinc Pongor, Yu-Ting Su, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2008
Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in boneAkihiro Yano, Shinji Tsutsumi, Shiro Soga, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2012
Heat shock protein 90α (HSP90α), a substrate and chaperone of DNA-PK necessary for the apoptotic responseStéphanie Solier, Kurt W Kohn, Bradley Scroggins, et al.
Oncology Letters|December 2, 2015
Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case reportHelen Gharwan, Yusuke Tomita, Min-Jung Lee, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 22, 2006
Curcumin is an inhibitor of p300 histone acetylatransferaseMonica G Marcu, Yun-Jin Jung, Sunmin Lee, et al.
Cancer Research|November 25, 2003
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cellsWanping Xu, Xitong Yuan, Yun Jin Jung, et al.
Expert Review of Hematology|April 28, 2017
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injuryPedro Cabrales, Scott Caroen, Arnold Oronsky, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2003
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrugMartin J Edelman, Kenneth Bauer, Shyam Khanwani, et al.
Molecular Pharmacology|September 4, 2010
Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinomaHye-Sik Kong, Sunmin Lee, Kristin Beebe, et al.
Plos One|October 23, 2013
Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effectsDror Luger, Yu-An Yang, Asaf Raviv, et al.
Trends in Cancer|April 30, 2020
MGMT Status as a Clinical Biomarker in GlioblastomaMadison Butler, Lorinc Pongor, Yu-Ting Su, et al.
Pageof 5